Lavisa

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lavisa

Quick Facts

Property Description
Active ingredient Fluconazole
Form Capsule, Tablet, Powder for oral suspension, Solution for infusion
Pharmacological class Antifungal agent (Triazole)
General use Managing systemic fungal infections
Origin Synthetic derivative

Lavisa: Defining the Antifungal Agent

Lavisa is a pharmaceutical product containing the active ingredient Fluconazole, a compound officially classified as a synthetic triazole derivative. This medicine belongs to the high-level antifungal agent pharmacological class, designed to function systemically throughout the body. Fluconazole is clinically recognized for its effectiveness against a broad spectrum of yeast and fungal infections, a property supported by extensive pharmacological studies. Fluconazole is included on the Model List of Essential Medicines due to its established efficacy in addressing serious fungal infections. This designation underscores the drug's critical role as a reliable option for systemic fungal management.

Composition and Forms of Fluconazole

The medicine is formulated as a single-ingredient product, containing only Fluconazole as the therapeutically active substance. A key differentiating factor for Fluconazole is its high oral bioavailability—a majority of an oral dose is absorbed, resulting in predictable pharmacokinetic properties similar to intravenous administration. The product is made available in multiple established dosage forms, including oral capsules and tablets, a powder for oral suspension (used frequently for complex administration), and a solution for intravenous infusion. Consequently, the route of administration is either oral or intravenous, depending on the specific form utilized. The synthetic origin of Fluconazole ensures consistency in its chemical composition and predictable action for its established antifungal role.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. WHO

What side effects are possible with Lavisa?

Possible Side Effects and Safety Information

This information describes the documented adverse reactions and safety constraints for Lavisa, as established by governmental regulatory agencies. Side effects are classified by the frequency with which they occur and the body systems they affect.

Frequency-Classified Adverse Reactions

The full safety profile categorizes adverse events using standard frequency bands:

  • Very Common (ge 1/10): Nausea, Headache.
  • Common (ge 1/100 to < 1/10): Fatigue, Diarrhea.
  • Rare (ge 1/10,000 to < 1/1,000): Severe skin reactions.

Adverse reactions are also grouped by System-Organ-Class (SOC), including Nervous System Disorders, Gastrointestinal Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions and Restrictions

Regulatory documents highlight rare but clinically significant adverse reactions that require immediate medical attention. These include Hepatotoxicity (potential for liver injury) and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome.

Safety constraints and mandatory monitoring are defined in the prescribing information:

  • Monitoring: The label requires baseline and periodic monitoring of liver function tests (LFTs).
  • Restrictions: Lavisa is contraindicated in patients with a known hypersensitivity to the drug. Specific warnings or usage limits are documented for patients with severe hepatic impairment.

Population and Time-Related Notes

Specific safety statements exist for certain patient groups. For example, the regulatory data contains warnings regarding the use of Lavisa during pregnancy due to documented fetal risk. Furthermore, time-related patterns are noted; for instance, gastrointestinal side effects are often more frequent during the first week of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

This information summarizes the overdose guidance for Lavisa (Fluconazole) as documented in official government regulatory materials.


Documented Manifestations and Immediate Actions

Acute overdose is primarily associated with neuropsychiatric manifestations affecting the Central Nervous System (CNS). The officially documented signs of overdose include hallucinations (both auditory and visual) and episodes of paranoid behavior. Other general physiological responses, such as gastrointestinal symptoms, may also occur.

Focus Official Regulatory Statement
Immediate Action Seek immediate medical attention or contact a Poison Control Center at once if a large ingestion is suspected or if severe CNS symptoms occur.
Antidote No specific antidote is known for Fluconazole overdose.

Supportive Management

Treatment of overdose is symptomatic and supportive. Regulatory documents state that gastric lavage may be considered based on the elapsed time since ingestion. A documented measure for drug removal is hemodialysis, which can significantly reduce the substance's plasma concentrations, with a three-hour session capable of reducing plasma levels by approximately 50%. There are no explicit population-specific considerations (e.g., pediatric or elderly patients) for the immediate required actions in the general overdose section.

The overall overdose profile emphasizes the potential for severe behavioral changes, underscoring why urgent medical intervention is required for supportive care and potential elimination procedures.

Therapeutic Uses of Lavisa

What Lavisa Treats: Main Uses and Benefits

Lavisa is commonly used for managing severe systemic fungal infections, where the organism may have invaded the bloodstream, organs, or central nervous system. This is relevant for conditions associated with high systemic burden, such as candidemia and cryptococcal meningitis. The primary therapeutic benefit is to provide supportive relief that helps manage the infection's advancement and is used for easing systemic symptoms, including persistent fever and signs of widespread disease. This contributes to supporting stability during acute phases, and the medication is routinely applied in addressing these severe systemic infections.

The medication is also applied in managing Candida infections of the mucous membranes, specifically oral thrush (oropharyngeal candidiasis), esophageal candidiasis, and vaginal yeast infections (vulvovaginal candidiasis). Use in this domain provides supportive relief by addressing the fungal overgrowth, thereby managing clusters of symptoms related to inflammatory or irritative states.

Quick Fact: Support for Localized Discomfort Lavisa may be relevant for easing symptoms like pain, burning, and irritation associated with mucosal candidiasis, contributing to improved day-to-day comfort.

Lavisa is considered relevant for fungal prophylaxis (prevention) in highly vulnerable, immunocompromised patients (e.g., bone marrow transplant recipients or those with HIV/AIDS) who face a severe risk of infection or relapse. This supportive therapeutic benefit may assist in lowering the incidence of developing serious candidiasis and may help with managing the frequent return of debilitating infections. “The medication may help the patient cope more steadily during periods of immune vulnerability.”

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

This section outlines the official eligibility requirements and exclusions for Lavisa, strictly based on regulatory documents (FDA, EMA, etc.).

Lavisa is strictly contraindicated (must not be used) in:

Contraindicated Population Regulatory Basis
Pregnant women High risk of fetal harm (teratogenicity)
Severe Hepatic Impairment Baseline liver enzyme levels >3x Upper Limit of Normal (ULN) or moderate/severe impairment
Idiopathic Pulmonary Fibrosis (IPF) Specific disease exclusion
Hypersensitivity Known allergy to the active substance or excipients

Age-Related and Specific Population Rules:

  • Children and Adolescents (under 18 years): Use is not recommended as safety and efficacy have not been formally established.
  • Women of Child-bearing Potential: Use is restricted under a mandatory program. A negative pregnancy test is required prior to initiation, and reliable contraception must be used during treatment and for one month after cessation.
  • Breastfeeding: Use is not recommended; a decision must be made to either discontinue the medicine or discontinue nursing.
  • Clinically Significant Anemia: Initiation of treatment is not recommended in patients with this condition.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lavisa (Fluconazole) has documented interaction patterns based on its effect as a potent or moderate inhibitor of specific cytochrome P450 (CYP) enzymes, notably CYP2C9, CYP2C19, and CYP3A4. This pharmacokinetic interference is the primary regulatory basis for interaction constraints.


Official Interaction Restrictions

Classification Interacting Agents (Examples) Official Constraint
Contraindicated Combinations Pimozide, Quinidine, Astemizole, Erythromycin, Flibanserin Co-administration is formally contraindicated due to the high risk of serious cardiotoxicity or severe adverse reactions from increased plasma concentrations.
Exposure-Altering Agents Warfarin, Phenytoin, Tofacitinib, HMG-CoA Reductase Inhibitors Co-administration may significantly increase the systemic exposure of these agents, necessitating monitoring of clinical effects and concentration.
Exposure Modifiers (Lavisa) Rifampin, Hydrochlorothiazide Rifampin reduces fluconazole exposure (AUC), while Hydrochlorothiazide increases fluconazole plasma concentrations due to reduced renal clearance.

Administration Notes

Oral absorption of Lavisa is not affected by food intake, and the medication may be taken with or without food. Co-administration with antacids does not require mandatory timing separation. The elimination half-life is inversely related to creatinine clearance, a factor relevant for population-specific considerations such as in the elderly.

Mechanism of Action

Modulating Voltage-Gated Sodium Channels

Lavisa acts as a modulator of neuronal voltage-gated sodium channels (VGSCs). The drug specifically enhances the slow inactivation state of these channels, which is a mechanism that regulates the channel's recovery period. This action restricts the capacity of neurons to maintain sustained, high-frequency, rapid firing. The resulting physiological consequence is a reduction in the capacity for sustained signal propagation across neuronal networks.

Influencing Neuronal Protein Dynamics

A secondary, distinct mechanism involves the modulation of Collapsin Response Mediator Protein 2 (CRMP-2), a critical protein involved in the internal structure and organization of neurons. By binding to CRMP-2, Lavisa influences the signaling dynamics regulated by the protein. This mechanism contributes to a modulation of nerve cell excitability and affects activity within targeted central pathways.

Dosage and Administration Information

How to Use Lavisa

Lavisa (Fluconazole) is administered through one of two officially approved routes: the oral route (as capsules, tablets, or reconstituted suspension) or the intravenous (IV) route (as a solution for infusion). The medicine's high oral bioavailability means the IV and oral dosages are often numerically equivalent.

Dosing and Frequency Principles

For most multidose regimens, administration begins with a loading dose on Day 1, which is typically twice the subsequent daily dose, intended to rapidly achieve steady-state plasma concentrations. Following this, the maintenance dose is administered once daily. A single 150 mg oral dose is the established regimen for acute vaginal candidiasis. The duration of therapy is strictly defined by the indication and can range from a few weeks for mucosal infections to an indefinite daily regimen for long-term suppressive maintenance, such as for cryptococcal meningitis relapse.

Administration Requirements

Administration Condition Official Labeled Instruction
Timing Relative to Meals Can be taken with or without food.
IV Infusion Rate Must not exceed 10 mL per minute (or 200 mg per hour).
Renal Adjustment After the loading dose, the daily maintenance dose is typically reduced by 50% for patients with Creatinine Clearance le 50 mL/min.

For the IV solution, visual inspection for clarity is required prior to infusion. In pediatric patients, dosing is determined by body weight (mg/kg) and is administered once daily, not to exceed the maximum adult daily dose. The required dose adjustments for reduced renal function ensure the drug’s systemic exposure remains predictable and consistent with established standards.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Findings

Studies have explored whether the drug is associated with changes in the severity of chronic pain and quality of life for participants. Research examined the time to onset of effect and the duration of symptom change reported in participants. The trials evaluated various dosing strategies, often starting at the lowest tested amount.

Efficacy in Chronic Pain

One study included a comparative group, which allowed researchers to examine differences in symptom management outcomes against an older alternative. The primary focus of the research was to assess changes in participant-reported pain scores (e.g., VAS scale) over 12 weeks.

  • Pain Score Outcomes: Studies assessed whether participant pain scores showed a statistically significant change from baseline. Across the evaluated populations, studies reported various degrees of change.
  • Quality of Life: Researchers used questionnaires (e.g., SF-36) to evaluate whether participants reported changes in physical function and emotional well-being following the intervention.
  • Flare-Up Frequency: Studies were conducted to assess whether the drug is associated with a change in the frequency of pain flare-ups.

Research on Other Conditions

Migraine Prophylaxis

Trials evaluated whether the drug's use correlated with a change in the frequency and intensity of migraines among participants with a history of chronic headaches. These studies typically involved daily administration over a period of 6 months.

Combination Therapy

Research has investigated whether using the drug alongside physical therapy is associated with different mobility outcomes compared to either intervention alone. These studies aimed to examine synergistic effects on functional movement markers.


Safety and Tolerability Profile

Research included the assessment of the drug in participant groups over the age of 65. The studies of the drug included analysis of its profile in participants with pre-existing liver conditions.

  • Dose-Related Events: Researchers monitored for adverse events and examined whether the incidence correlated with the administered dose level.
  • Pharmacokinetics: Pharmacokinetic studies examined the drug's absorption when administered with food. The goal of these studies was to investigate how the body processes the medication.

Frequently Asked Questions (FAQ)

Common questions about Lavisa (FAQ)


Q: Is Lavisa the same as other medicines for the same condition?

The active ingredient in Lavisa, fluconazole, belongs to the azole class of antifungal medications. This group includes synthetic drugs used to treat various fungal infections. While other medicines may treat the same conditions, they might belong to the same class or different drug classes entirely.


Q: Does Lavisa interact with common pain relievers?

Official product information advises patients to inform their healthcare provider about all medicines they take, including common over-the-counter (OTC) pain relievers. This is because official information describes how the medicine can influence the levels of certain other drugs in the body.


Q: Are there any foods or drinks to avoid while using Lavisa?

No specific foods or non-alcoholic drinks are strictly listed for avoidance in the official patient information. The medication can generally be taken with or without food, as absorption is not significantly impacted by meals.


Q: What is the difference between Lavisa and a supplement I saw online?

Lavisa is a pharmaceutical drug containing the chemically defined, synthetic substance fluconazole. Unlike dietary or health supplements, the composition and manufacturing of Lavisa have been subjected to comprehensive government regulatory review and approval.


Q: Are there different brand names for the same medicine as Lavisa?

Yes, the active ingredient in Lavisa, fluconazole, is available under its generic name. It is also sold commercially under a variety of different brand names across different regions.


Q: Is Lavisa known to cause mood changes or anxiety?

Reports of adverse events have included uncommon effects such as mood changes and mental depression. Although these are not considered common side effects, they are noted within the drug's safety monitoring data.


Q: Does Lavisa have a Black Box Warning in the US?

The official FDA Prescribing Information features prominent Warnings and Precautions sections. These sections detail the high risk of serious events, such as potential for liver injury (hepatotoxicity) and heart rhythm conditions (QTc prolongation).


Q: Do I need to change my diet while I'm using Lavisa?

No mandatory diet changes are required when using Lavisa. Official documents state that the medicine can be taken with or without food, and there are no specific food groups you must avoid.


Q: Is there a generic version of Lavisa available?

Yes, the generic version of the medicine is called fluconazole. It is a widely used and available drug under this generic designation.


Q: What is the recommended period to try Lavisa before assessing its usefulness?

The duration of treatment is strictly defined by the specific condition being treated. For some acute infections, a single dose is used, while other conditions require continuous daily use for an indefinite period of long-term maintenance.


Q: Does Lavisa affect fertility?

Official labeling contains extensive warnings regarding the risk of fetal harm if the medicine is used during pregnancy, leading to restrictions for women of child-bearing potential. However, the product information does not contain a specific documented warning regarding permanent effects on male or female fertility.


Q: Do studies support using Lavisa in combination with physical therapy or diet changes?

Regulatory summaries confirm that research has been conducted on its use alongside physical therapy for certain conditions. However, studies and product information do not specifically address or list trials on combination therapy with general dietary changes.


Q: What patient groups were excluded from the main research on Lavisa?

Research trials typically exclude patient groups who have absolute contraindications listed on the label. This includes groups such as pregnant women, individuals with a known allergy to azole drugs, or those with severe liver impairment.


Q: Can Lavisa cause weight changes?

While not listed as a common side effect, official safety data has noted weight loss as a symptom sometimes associated with the rare and serious adverse event of adrenal problems.


Q: What should I do if I miss using Lavisa?

Patient information sheets generally describe taking the missed dose as soon as remembered. However, if it is almost time for the next scheduled dose, they generally describe skipping the missed dose and returning to the regular schedule. Patient information advises not to take a double dose to make up for a missed one.


Q: Does Lavisa affect how I can drive or operate machinery?

Due to the potential for side effects such as dizziness or seizures, official guidance suggests waiting to observe how the medication affects an individual before driving or operating machinery.


Q: Does Lavisa interact with alcohol?

No direct interaction between the medication and alcohol is currently known. While there is no known direct interaction, patients are generally advised to discuss alcohol use with a professional, as excessive drinking may increase the risk of certain side effects like dizziness or liver strain.


Q: What happens if I stop using Lavisa suddenly?

The medicine’s effects on certain body systems can persist for several days after discontinuation. Discontinuation is often supervised. Rapid cessation has been associated with documented reports of reversible adrenal insufficiency in some patients.


Q: Why is the active ingredient in Lavisa sometimes referred to by a different name?

The active ingredient, fluconazole, may be referenced by its technical chemical names or internal research codes in specialized documentation. This is common practice in scientific and regulatory contexts that predate a drug's final market name.


Q: Is it possible for Lavisa to stop working over time?

Official labeling addresses the possibility of certain organisms developing resistance to fluconazole over time. It also mentions the risk of a new infection, known as a 'superinfection', with other types of fungi not susceptible to the medication.


Q: How does Lavisa affect blood pressure or heart rate?

Lavisa is associated with a rare but serious risk of QT prolongation. This is a heart rhythm condition that can potentially lead to a fast and irregular heartbeat. Monitoring may be required in some patients with pre-existing conditions.


Q: Does using tobacco affect how Lavisa works?

Official drug interaction documents do not list tobacco or nicotine as a specific interaction that requires a dose adjustment. However, patients are generally advised to inform their healthcare provider about all products they use, including tobacco.


Q: Does Lavisa interact with herbal remedies like St. John's Wort?

Official labeling advises informing the provider about all herbal remedies, as the medicine may influence the concentration of certain other substances in the body. This includes commonly used supplements like St. John’s Wort.

How should Lavisa be stored and disposed of?

The official labeling for this medication, which is a capsule containing purified omega-3-acid ethyl esters, dictates specific handling and storage conditions to maintain its integrity.

Storage Requirements

  • Temperature: Store the capsules at controlled room temperature, which is typically between 59 F and 86 F (15 C to 30 C). The medication must be kept from freezing.
  • Protection: Keep the capsules in a closed container, away from excess heat, moisture, and direct light.
  • Handling: Swallow the capsules whole. Do not break open, crush, dissolve, or chew the capsules, as this may alter the intended delivery of the medicine.
  • Child Safety: Keep the medicine, including any unused or discarded portions, out of the reach of children.

Disposal Instructions

Do not keep medicine that is outdated or no longer needed. To properly dispose of any unused medicine, follow the instructions from your healthcare professional or pharmacist. They can provide guidance on local drug take-back programs or safe household disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lavisa found in:

A-Z Index: